A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment

Part of paid clinical trials in Columbus, Georgia.

Sponsor
Astellas Pharma Inc
Study ID
NCT01007292
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • YM155 — DRUG
    intravenous infusion
  • Rituximab — BIOLOGICAL
    intravenous infusion

Study Details

The purpose of this study is to evaluate response rate, survival, safety and tolerability of YM155 given in combination with rituximab in subjects with Non-Hodgkin's Lymphoma.

Key Dates

Start date
Nov 30, 2009
Status verified
Sep 2015
Primary completion
Mar 31, 2013
Completion
Jun 30, 2015

Study Design

Enrollment
43 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: YM155 plus rituximab

Primary Outcome Measure

Objective response rate (Confirmed Complete Remission +Confirmed Partial Remission) [ Time Frame: After the last non-progressing subject receives 8 cycles of treatment or discontinues the treatment ]

Locations (6)

FacilityCityStateZIPSite coordinators
Site US2778 John B. Amos Cancer CenterColumbusGeorgia31904-
Site US55 Loyola University Hospital - MaywoodMaywoodIllinois60153-
Site US9 Mount Sinai School of MedicineNew YorkNew York10029-
Site US2802 Mecklenburg Medical GroupCharlotteNorth Carolina28204-
Site US2149 Gabrail Cancer Center ResearchCantonOhio44718-
Site US402 University of Texas Health Science Center - San AntonioSan AntonioTexas78229-

Find similar trials in Columbus, GA

By research site
Site US2778 John B. Amos Cancer Center· Columbus, GASite US55 Loyola University Hospital - Maywood· Maywood, ILSite US9 Mount Sinai School of Medicine· New York, NYSite US2802 Mecklenburg Medical Group· Charlotte, NCSite US2149 Gabrail Cancer Center Research· Canton, OHSite US402 University of Texas Health Science Center - San Antonio· San Antonio, TX

Related Studies